Clinical Management of CINV

  • Rudolph M. NavariEmail author


Antiemetic guidelines have been published by NCCN [1], ASCO [2], and MASCC [3]. These guidelines form the basis for the recommendations for the management of CINV. As new information and new studies emerge, the guidelines will evolve to provide the highest quality evidence-based clinical practice.


Emetogenic Chemotherapy Highly Emetogenic Chemotherapy Moderately Emetogenic Chemotherapy Oral Olanzapine Antiemetic Guideline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):232–243CrossRefGoogle Scholar
  2. 2.
    Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198CrossRefPubMedGoogle Scholar
  3. 3.
    NCCN Clinical Practice Guidelines in Oncology version 1 2012. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: Accessed 30 Sept 2015
  4. 4.
    Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947CrossRefPubMedGoogle Scholar
  5. 5.
    Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 1:89–103PubMedGoogle Scholar
  6. 6.
    Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294CrossRefPubMedGoogle Scholar
  7. 7.
    Hickok JT, Roscoe JA, Morrow GR et al (2005) 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 6:765–772PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663CrossRefPubMedGoogle Scholar
  9. 9.
    Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195CrossRefPubMedGoogle Scholar
  10. 10.
    Rapoport BL, Jordon K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423–431CrossRefPubMedGoogle Scholar
  11. 11.
    Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Dev Ther 9:155–161Google Scholar
  12. 12.
    Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127–1133CrossRefPubMedGoogle Scholar
  13. 13.
    Navari RM (2007) Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 5:51–59PubMedGoogle Scholar
  14. 14.
    Einhorn LH, Brames ML, Dreicer R et al (2007) Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293–1300CrossRefPubMedGoogle Scholar
  15. 15.
    Albany C, Brames ML, Fausel C et al (2012) Randomized, double-blind, placebo-controlled, phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 antagonist plus dexamethasone in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol 30:3998–4003CrossRefPubMedGoogle Scholar
  16. 16.
    Stiff PJ, Fox-German MP, Kiley K et al (2013) Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19:49–55CrossRefPubMedGoogle Scholar
  17. 17.
    Jordan K, Jahn F, Jahn P et al (2011) The NK-1 receptor antagonist aprepitant in high-dose chemotherapy (high dose melphalan and high dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transpl 46:784–789CrossRefGoogle Scholar
  18. 18.
    Navari RM (2012) Treatment of chemotherapy-induced nausea. Community Oncol 9:20–26CrossRefGoogle Scholar
  19. 19.
    Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285–1291CrossRefPubMedGoogle Scholar
  20. 20.
    Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1–7CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Cancer Care Program, Central and South America, World Health OrganizationIndiana University School of Medicine South BendSouth BendUSA

Personalised recommendations